ICCC

ImmuCell Corporation develops and commercializes veterinary biologics focused on calf health, specifically scours prevention products. Its primary offering, First Defense, provides immediate passive immunity to newborn calves against E. coli, coronavirus, and rotavirus through a single-dose gel or bolus administered at birth. The company operates in the animal health sector, targeting dairy and beef cattle producers primarily in the United States. ImmuCell's products are approved by the USDA Veterinary Center for Biologics, ensuring compliance with regulatory standards in the veterinary market.